Compare SAH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | EVO |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 778.3M |
| IPO Year | 1997 | 2007 |
| Metric | SAH | EVO |
|---|---|---|
| Price | $74.48 | $1.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $78.25 | $7.00 |
| AVG Volume (30 Days) | ★ 174.2K | 42.2K |
| Earning Date | 04-30-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | ★ $9,951,630,000.00 | N/A |
| Revenue This Year | $4.61 | $1.37 |
| Revenue Next Year | $4.16 | $10.05 |
| P/E Ratio | $20.89 | ★ N/A |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $54.11 | $1.72 |
| 52 Week High | $113.67 | $4.27 |
| Indicator | SAH | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 37.45 | 27.66 |
| Support Level | $59.77 | N/A |
| Resistance Level | $82.75 | $1.97 |
| Average True Range (ATR) | 2.36 | 0.04 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 10.07 | 8.11 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 107 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores in 10 states, 16 collision centers, and 20 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 56% of new-vehicle revenue. BMW is the largest brand at about 23%. 2025 revenue was $15.2 billion, with Texas and California constituting 51% of the total. EchoPark's portion was $2.1 billion.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.